703results about "Testing medicinal preparations" patented technology

Disclosed are a method, a device, and an information processing program for determining, by using refractive index distribution data pertaining to an object to be observed, the region of a cell that has undergone programmed cell death in the object to be observed.

The present invention provides methods and compositions for treating cancer and / or autoimmune diseases by modulating the expression and / or activity of IGSF8 and its binding ligand. Pharmaceutical compositions include, but are not limited to, antibodies that specifically bind to human IGSF8 and have the activity of inhibiting IGSF8-mediated immunosuppression in a subject in need thereof. Pharmaceutical compositions may include, but are not limited to, antibodies that specifically bind to human IGSF8 and have the activity of inhibiting IGSF8-mediated immunosuppression in a subject in need thereof.

Disclosed are compositions and methods useful for targeting and internalizing molecules into cells of interest and for penetration by molecules of tissues of interest. The compositions and methods are based on peptide sequences that are selectively internalized by a cell, penetrate tissue, or both. The disclosed internalization and tissue penetration is useful for delivering therapeutic and detectable agents to cells and tissues of interest.

The invention provides a traditional Chinese medicine preparation quality detection method and system based on multi-dimensional data analysis, and belongs to the technical field of traditional Chinese medicine preparation quality detection. The method comprises the following steps: acquiring mass spectrum data and nuclear magnetic resonance data of various active components in a preparation to generate a multi-dimensional chemical characteristic data set; synchronously collecting corresponding data of the medicinal raw materials, and constructing a process and environment association database; constructing a chemical and process coupling analysis model; and monitoring the production process in real time to obtain the dynamic chemical fingerprint spectrum. By constructing a full-component chemical map and associating the full-component chemical map with process and environmental parameters and combining clinical curative effect data to establish a drug effect and component response curved surface model, the limitation that only a few index components are concerned in traditional detection is broken through, so that a detection result can accurately reflect the multi-target and overall regulation characteristics of the traditional Chinese medicine preparation, and the detection accuracy is improved. The problem that the components are qualified but the curative effect is poor due to single detection dimension is avoided, and the relevance between quality detection and the clinical curative effect is remarkably improved.

The present invention relates to a method and apparatus for predicting the effect of the co-administration of a secondary active compound on the bioavailability of a primary active compound.

The invention relates to the technical field of traditional Chinese medicines, in particular to a processing method and a quality control method for toxicity reduction and efficacy enhancement of radix cynanchi bungei. According to the method, the content of alangiine, the content of ellagic acid, the common peak area of characteristic peaks and the content of water-soluble extracts in the wine-roasted berberis scenting decoction pieces are measured by adopting a high performance liquid chromatography (HPLC) method, and subjective assignment is carried out on the characters of the wine-roasted berberis scenting decoction pieces by combining Delphi evaluation to serve as evaluation indexes; the method comprises the following steps: determining the weight coefficient of each index by adopting an analytic hierarchy process-index repeatability correlation mixed weighting method (AHP-CRITIC), and screening the optimal wine roasting process of the Zhuang medicine Tibetan scene by combining the three factors of the frying temperature, the frying time and the yellow wine amount with star point design (CCD)-effect surface (RSM) according to the coefficients. And finally determining the optimal process of stir-frying the radix berberidis with wine as follows: the stir-frying temperature is 150 DEG C, the stir-frying time is 16min, the amount of yellow rice wine is 10%, and moistening is performed for 24h.

The present invention aims to provide a method for evaluating the serotonin reuptake inhibitory effect of a composition containing valerian extract. [Solution] The present invention provides a method for evaluating antidepressant effects, which involves quantitatively analyzing one or more components contained in at least a part of a plant of the genus Valerian or a processed product thereof, and evaluating the antidepressant effect of the test substance by referring to the results of the quantitative analysis and criteria for antidepressant effect.

To provide a method for analyzing Gla modification levels in vitamin K dependent protein.SOLUTION: An analytical method at least comprises the steps of: digesting vitamin K dependent protein with chymotrypsin, to cleave a Gla domain, to obtain Gla domain peptides; and sorting the Gla domain peptides by liquid chromatography according to the Gla modification levels. Such an analytical method enables the Gla modification levels to be determined quantitatively and qualitatively.SELECTED DRAWING: Figure 2

In some examples, a sensor for detecting dextrose includes at least one working electrode including Cu and being configured to electro-oxidize dextrose in an aqueous solution. The sensor further includes at least one counter electrode. In some examples, a system includes a fluid line, a dextrose container, a peritoneal dialysis container, and the sensor. The fluid line is configured to transport water. The dextrose container is configured to introduce dextrose in the fluid line to generate a peritoneal dialysis composition comprising the water and dextrose. The peritoneal dialysis container is downstream of the dextrose container and configured to receive the peritoneal dialysis composition. The sensor may be configured to detect dextrose in the peritoneal dialysis composition.

The invention belongs to the technical field of dissolution instrument calibration, and particularly relates to a dissolution instrument rotating shaft calibration device which comprises a laser displacement sensor for calibrating a shaft rod of a dissolution instrument and a perpendicularity calibration unit. The base body is detachably arranged at the cup opening of the dissolution cup through a limiting buckling assembly; the bending plate is arranged on the base body; the power assembly is arranged on the bending plate, is matched with the base body and is used for driving the bending plate to do circumferential rotation around the cup opening of the dissolution cup; the radial pushing assembly is used for arranging the laser displacement sensor or the perpendicularity calibration unit on the bending plate and pushing the laser displacement sensor or the perpendicularity calibration unit to move in the radial direction of the dissolution cup; according to the scheme, the laser displacement sensor and the perpendicularity calibration unit can be in an automatic state to calibrate the shaft lever, so that the calibration accuracy of the rotating shaft of the dissolution tester can be improved.

The invention provides a method for evaluating the minimum inhibitory concentration of compound amoxicillin powder, and belongs to the technical field of compound amoxicillin, and the method comprises the following steps: (1) simulating a gastric acid environment, and respectively adding different compound amoxicillin powder samples to obtain different sample solutions; (2) simulating a small intestine environment for different sample solutions obtained in the step (1); and (3) sampling different sample solutions after the step (2), measuring the minimum inhibitory concentration, and comparing the effect of the compound amoxicillin powder sample to evaluate. The invention provides a method for evaluating the minimum inhibitory concentration of compound amoxicillin powder. The method is simple to operate and can quickly and accurately evaluate the effect of the compound amoxicillin powder.

Provided is a novel polypeptide. A polypeptide according to one embodiment of the present invention is a polypeptide comprising an amino acid sequence shown by SEQ ID NO: 1 or 3, or is a variant thereof. A polypeptide according to another embodiment of the present invention is a polypeptide comprising an amino acid sequence shown by SEQ ID NO: 9 or 11, or is a variant thereof.

The present invention relates to the field of biomedicine, and in particular to a method for evaluating generation of an ADA by an immune agonist conjugate and a use thereof.

The invention discloses a method for screening a medicine for treating liver injury caused by polygonum multiflorum based on biochemical indexes and application of the method. The method comprises the following steps: constructing a polygonum multiflorum induced liver injury animal model; the target drug is applied to the fleece-flower root-induced liver injury animal model, the fleece-flower root-induced liver injury animal model is administered according to a fixed time period, and the leucoglobulin ratio, the total protein content and the globulin content in the blood plasma of the fleece-flower root-induced liver injury animal model are detected. The leucoglobulin ratio, the total protein content and the globulin content in the rat plasma are used as indexes for evaluating the medicine for treating the liver injury caused by the polygonum multiflorum. According to the scheme, the method for screening the medicine for treating the liver injury of the polygonum multiflorum is simple and easy to implement, the medicine for treating the liver injury of the polygonum multiflorum can be effectively screened by taking the white ball ratio, the total protein content and the globulin content in the blood plasma of an animal with the liver injury caused by the polygonum multiflorum as detection indexes, and a theoretical basis is also provided for clinical prevention and diagnosis of the liver injury of the polygonum multiflorum.

The invention discloses a three-dimensional heart chip device. The device comprises a pneumatic control layer, a flexible functional film layer and a microfluidic culture layer, wherein the flexible functional film layer is integrated with a stretchable microelectrode array with a snakelike structure, and the microfluidic culture layer is arranged on the flexible functional film layer; wherein the pneumatic control layer is used for driving the flexible functional film layer to generate periodic deformation and applying mechanical tensile strain to cardiac muscle tissues in the microfluidic culture layer, and meanwhile, the stretchable microelectrode array of the snake-shaped structure synchronously deforms along with the flexible functional film layer and keeps conformal electric contact with the cardiac muscle tissues, so that the mechanical tensile strain is applied to the cardiac muscle tissues in the microfluidic culture layer. The electrophysiological signals are monitored in the dynamic mechanical stretching process. The technical problem that in the prior art, stable electrophysiological monitoring cannot be carried out while dynamic mechanical stretching is applied is solved, physiologically-related mechanical stimulation can be applied to three-dimensional cardiac muscle tissue to promote maturity of the three-dimensional cardiac muscle tissue, and long-term and stable in-situ electrophysiological signal monitoring is achieved in the process; and a more accurate in-vitro model is provided for drug screening and disease research.

A computer-implemented method for administering a drug to a subject is provided, the method including administering the drug to the subject using a controllable pump, contacting an electrochemical aptamer-based sensor capable of detecting the drug with a bodily fluid (e.g., in situ interstitial fluid) of the subject, receiving a series of output values ​​of the electrochemical aptamer-based sensor over a period of time, and controlling the pump using the series of output values.

The present invention provides a method for screening for a telomerase reverse transcriptase (TERT) phosphorylation inhibitor using TERT or a fragment thereof, and a TERT kinase.

In one aspect, a novel method that allows for evaluation of an RTK activity is provided. Provided is a method for evaluating an RTK activity, the method including: a step (A1) for determining diffusion dynamics A1 of the RTK by contacting a target substance with a cell that expresses a labeled RTK on a cell membrane, a step (B1) for determining diffusion dynamics B1 of the RTK by contacting the target substance and a ligand that activates the RTK with the cell that expresses the labeled RTK on a cell membrane, a step (C1) for calculating a ratio of the diffusion dynamics A1 of the RTK obtained at the step (A1) and the diffusion dynamics B1 of the RTK obtained at the step (B1), and a step (D1) for evaluating an effect of the target substance on an RTK activity by comparing the ratio of the diffusion dynamics obtained at the step (C1) with a threshold; and at the step (D1), when the ratio of the diffusion dynamics obtained at the step (C1) is equal to or greater than the threshold, it can indicate that the target substance has an effect on a molecular function of the RTK.

Described herein are systems, methods, and devices for pathogen identification. The system includes a housing configured to receive a sample containing a pathogen, a pipetter system disposed within the housing, a centrifuge disposed within the housing, a mechanical agitator disposed within the housing, and a controller. The controller is configured to transfer the sample to a processing tube using the pipetter system, centrifuge the processing tube using the centrifuge to concentrate the pathogens in the sample, remove liquid from the processing tube using the pipetter system to leave the concentrated pathogens in the processing tube, add a lysis buffer to the processing tube using the pipetter system, move the processing tube to a mechanical agitator using the pipetter system, and agitate the processing tube using the mechanical agitator to lyse the concentrated pathogens. The system is further configured to perform PCR using nucleic acids extracted from the sample.

A connection structure of a dissolution rate instrument and a liquid chromatograph comprises a connector assembly, a first connector assembly is connected between the output end of the dissolution rate instrument and the outer side of a frame of the liquid chromatograph, and a second connector assembly and a third connector assembly are connected between the inner side of the frame of the liquid chromatograph and the input end of a sample injection bottle in the liquid chromatograph. The output end of the sample introduction bottle is connected with the input end of the dissolution rate instrument through a fourth joint assembly. The device has the beneficial effects that the connection of a dissolved sample from a dissolution rate instrument to a liquid chromatograph is realized, so that the data accuracy and the experiment efficiency can be remarkably improved, errors and risks caused by manual operation are reduced, the flexible configuration and rapid replacement of the dissolution rate instrument and a liquid chromatography system are realized, and the working efficiency is improved. And the analyzed sample can be returned to the dissolution rate instrument in a circulating manner, so that the loss of the sample is reduced.

The present invention provides a pharmaceutical composition useful for treating a disease caused by a target tissue, its active ingredient, a screening method for the pharmaceutical composition and the active ingredient, and a manufacturing method. [Solution] The present invention provides an antigen-binding molecule comprising an antigen-binding domain whose antigen-binding activity changes depending on the concentration of a target tissue-specific compound. The antigen-binding molecule comprises an Fc region contained in a constant region of a specific sequence, and an FcγR-binding altered Fc region whose binding activity to Fcγ receptors is higher than the binding activity to Fcγ receptors of the Fc region of native human IgG. Use of the antigen-binding molecule enables target tissue-specific treatment of various diseases caused by target tissues.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to stasis-removing and pain-relieving pills and a quality detection method thereof. The stasis-removing and pain-relieving pill is prepared by taking radix paeoniae alba, rhizoma corydalis, radix paeoniae rubra, angelica sinensis, ligusticum wallichii, rhizoma cyperi, rhizoma zingiberis, fennel and astragalus membranaceus as raw materials and taking 10% starch slurry as an adhesive. The quality detection method of the stasis-removing and pain-relieving pill comprises general inspection, microscopic identification and thin-layer chromatography identification. And high performance liquid chromatography content determination. According to the present invention, by researching the preparation process and the quality standard of the stasis removing and pain relieving pill, the new thought and the new method are provided for the development of the traditional Chinese medicine preparation, the excellent choice is hopefully provided for the common gynecologic symptoms such as irregular menstruation, dysmenorrhea, postpartum blood stasis abdominal pain and the like, and the pain caused by the illness is relieved.

The utility model discloses health-care product detection equipment capable of quantitatively adding a detection agent, which belongs to the field of health-care product detection equipment and is characterized in that a rotating motor is mounted at the lower end of a worktable, a rotating table is arranged at the upper end of the worktable and connected with the rotating motor, a plurality of detection positions are mounted at the upper end of the rotating table, and the rotating table is driven by the rotating motor to rotate; the relative position of the detection position and the detection assembly is further changed; a quantifying box is connected to the support through an L-shaped frame, a first electric push rod is arranged at the outer end of the quantifying box, a butterfly valve is connected to an opening in the upper end of the quantifying box, and a bottom gate is connected to an opening in the lower end of the quantifying box. The electric push rod accurately controls the adding amount of the detection agent to ensure accurate results. The butterfly valve and the bottom gate prevent leakage and guarantee safety. And stability and reliability of mechanism connection and bolt fixation are ensured. Opening and closing of the valve are accurately controlled, and smooth detection is guaranteed. Automatic design simplifies operation and improves detection convenience. The design of the telescopic push rod and the butt joint port ensures stable output and improves safety.

Provided are a novel antithrombotic antibody targeting a blood coagulation factor FIXa-FVIIIa binding site and an application thereof.SOLUTION: The present invention provides a novel antithrombotic antibody, which targets FIXa and has unique properties, specifically targets the binding site of blood coagulation factors FIXa and FVIIIa, reduces the formation of FVIIIa-FIXa complex, blocks the conversion of FX to FXa, and exerts an antithrombotic effect. The antibody of the present invention has an appropriate antithrombotic performance and a large effective therapeutic concentration window, but does not increase the bleeding risk, which can achieve the need for moderate antithrombosis and effectively avoid the bleeding problem caused by excessive action in clinical applications. The present invention also discloses methods of screening for drugs that target the FIXa-FVIIIa binding site.SELECTED DRAWING: Figure 1A

The invention discloses an anti-osteoporosis drug screening kit, and belongs to the technical field of drug screening, the anti-osteoporosis drug screening kit comprises a device base, one side of the top of the device base is fixedly connected with a constant temperature supporting mechanism, the center of the constant temperature supporting mechanism is provided with a rotation continuous mechanism, and the rotation continuous mechanism is provided with a rotation mechanism. A plurality of microporous RANK protein detection plates are placed on the rotary continuous mechanism, an RANKL solution temporary storage refrigerating box is arranged in the center of the top of the constant-temperature supporting mechanism, a source plate temporary storage mechanism is arranged on one side of the front end of the top of the device base, and a multidirectional driving mechanism is arranged at the top of the device base. And a cleaning mechanism is mounted on one side of the multidirectional driving mechanism. By designing the constant-temperature supporting mechanism and the rotating continuous mechanism, multiple groups of compounds can be screened in sequence, circulating continuous operation is achieved, the time utilization rate is greatly increased, and then the compound screening efficiency is improved.

A system (100), method and computer program product are disclosed for determining conformity of a fingerprint of a sample (201) with at least one corresponding expected fingerprint of said sample. The system obtaining a measured spectrum (211) as the fingerprint of the sample (201). The measured spectrum is the result of a measurement reflecting a current chemical and physical state (C1) of the sample obtained by vibrational spectroscopy. The system accesses a spectrum library (300) comprising a plurality (311) of calibrated reference spectra (311-1 to 311-n). A kNN module (110) identifies a subset of the reference spectra in the spectrum library by determining representations (311k) of k nearest neighbor reference spectra in the vicinity of a corresponding representation (311s) of the measured spectrum (211) in accordance with predefined metrics. An averaged reference spectrum module (120) computes, based on the identified subset, an averaged reference spectrum representing the at least one corresponding expected fingerprint, and computes the standard deviation in each data point of the k nearest neighbor reference spectra. A difference spectrum module (130) determines a difference spectrum by computing the difference between measured spectrum and averaged reference spectrum divided by the corresponding standard deviation in each data point. A conformity module (140) determines deviating data points where the value of the difference spectrum exceeds a predefined deviation threshold, and determines conformity (145) in accordance with a predefined conformity rule (141) based on the data points exceeding said predefined deviation threshold.